Dowling & Yahnke’s Acadia Pharmaceuticals ACAD Stock Holding History

Dowling & Yahnke’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-9,000	Closed	-$286K	–	255
2014 Q4	$286K	Hold	9,000	–	–	0.04%	226
2014 Q3	$223K	Sell	9,000 -1,000	-10%	-$23.4K	0.03%	238
2014 Q2	$226K	Hold	10,000	–	–	0.03%	251
2014 Q1	$243K	Hold	10,000	–	–	0.03%	247
2013 Q4	$250K	Hold	10,000	–	–	0.04%	224
2013 Q3	$275K	Hold	10,000	–	–	0.04%	209
2013 Q2	$181K	Buy	+10,000	New	+$138K	0.03%	225

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Dowling & Yahnke's ACAD Position: Q1 2015 in Review

Dowling & Yahnke sold out of Acadia Pharmaceuticals (ACAD) in Q1 2015, closing a stake of 9,000 shares — an estimated $286K sold.

Dowling & Yahnke first reported a position in ACAD in Q2 2013 and held it in 7 quarters. The position peaked at $286K in Q4 2014. 193 funds tracked by Wall St. Rank hold ACAD as of Q1 2015.

Dowling & Yahnke reported no remaining Acadia Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Dowling & Yahnke sold 9,000 Acadia Pharmaceuticals shares in Q1 2015, an estimated $286K.
Dowling & Yahnke first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Dowling & Yahnke's Acadia Pharmaceuticals position peaked at $286K in Q4 2014.
193 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2015.

Based on Dowling & Yahnke's 13F filing for Q1 2015, filed 10 Apr 2015.